<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-142599" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cardiac Sarcoidosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hussain</surname>
            <given-names>Kifah</given-names>
          </name>
          <aff>Northwestern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shetty</surname>
            <given-names>Mrin</given-names>
          </name>
          <aff>University of Chicago (NorthShore)</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kifah Hussain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mrin Shetty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-142599.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation, predominately affecting the myocardium.&#x000a0;Approximately 25% of patients with systemic evidence of sarcoidosis have cardiac disease involvement. Diagnosing cardiac sarcoidosis is often challenging as the clinical presentation is variable. Patients frequently present with symptoms of heart failure, conduction abnormalities, ventricular arrhythmias, or sudden cardiac death, all of which can be secondary to numerous disease processes. Additionally, there is no single diagnostic test for sarcoidosis, and while endomyocardial biopsy has a high specificity for cardiac sarcoidosis, it is invasive and insensitive.</p>
        <p>Cardiac sarcoidosis is a rare condition with a poor prognosis. The left ventricular ejection fraction is the most important predictor of mortality in cardiac sarcoidosis. The available treatments for cardiac sarcoidosis are nonspecific and may cause adverse systemic effects. However, early diagnosis and intervention can improve outcomes for patients with this uncommon infiltrative cardiomyopathy. This activity for healthcare professionals reviews the etiology, epidemiology, pathophysiology, symptomatology, diagnostic strategies, and management recommendations for patients with cardiac sarcoidosis and highlights the critical role of the interprofessional team in the management of this cardiac disorder.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients who may have cardiac sarcoidosis as suggested by their clinical history.</p></list-item><list-item><p>Compare and contrast the efficacy, risks, and benefits of the diagnostic modalities commonly employed for patients with possible cardiac sarcoidosis.</p></list-item><list-item><p>Select the most appropriate therapeutic intervention for a patient with cardiac sarcoidosis by applying evidence-based guidelines.</p></list-item><list-item><p>Develop and implement effective interprofessional team strategies to improve outcomes for patients with cardiac sarcoidosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=142599&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=142599">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-142599.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sarcoidosis is a multisystem granulomatous disorder resulting from a combination of environmental, genetic, and inflammatory factors causing the accumulation of noncaseating granulomas in many organs, such as the lungs, eyes, skin, lymph nodes, and heart. Cardiac sarcoidosis (CS) refers to granulomatous inflammation that affects the heart in isolation or as part of systemic sarcoidosis.<xref ref-type="bibr" rid="article-142599.r1">[1]</xref>&#x000a0;Based on imaging and autopsy findings, CS occurs in approximately 25% of patients with sarcoidosis. Cardiac sarcoidosis is a rare condition with a generally poor prognosis.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref></p>
        <p>The diagnosis of CS is often difficult. Sarcoidosis is sometimes considered a diagnosis of exclusion because there is no single diagnostic laboratory, radiologic, or other test. The clinical presentation of sarcoidosis, generally and CS particularly, is highly variable. Cardiac sarcoidosis may present with symptoms of heart failure, sudden cardiac death, ventricular arrhythmia, myocardial infarction, or atrioventricular (AV) block; the most common presentations are conduction system disorders and heart failure.<xref ref-type="bibr" rid="article-142599.r3">[3]</xref>&#x000a0;Systemic clinical manifestations of sarcoidosis include signs and symptoms of other organ involvement, such as ocular, neurological, and cutaneous sarcoid.<xref ref-type="bibr" rid="article-142599.r4">[4]</xref>&#x000a0;Approximately 25% of patients have isolated cardiac sarcoidosis without systemic involvement, and it is debatable if the prognosis differs from systemic sarcoidosis with cardiac manifestations.<xref ref-type="bibr" rid="article-142599.r1">[1]</xref><xref ref-type="bibr" rid="article-142599.r5">[5]</xref>&#x000a0;The most important prognostic indicator in patients with CS is left ventricle ejection fraction (LVEF). Endomyocardial biopsy, an invasive procedure, has a low diagnostic yield due to the patchy involvement of the myocardium. Therefore, advanced imaging studies&#x000a0;are employed to enhance the accuracy of diagnosis, particularly in patients without extracardiac manifestations of sarcoidosis.</p>
      </sec>
      <sec id="article-142599.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Cardiac sarcoidosis is likely the result of various environmental, genetic, and immune dysregulation factors.&#x000a0;It has been postulated that sarcoidosis may result from an exaggerated immune response to microorganisms and tissue antigens, resulting in chronic granulomatous inflammation, even without an infectious agent.<xref ref-type="bibr" rid="article-142599.r6">[6]</xref>&#x000a0;</p>
        <p>Approximately&#x000a0;5% to 16% of&#x000a0;patients with sarcoidosis have a family history of the disease; a correlation between monozygotic twins suggests a genetic component.<xref ref-type="bibr" rid="article-142599.r7">[7]</xref>&#x000a0;Certain genes have also been associated with sarcoidosis, including class II MHC HLA-DR3.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref>&#x000a0;&#x000a0;</p>
        <p>Environmental factors and the resultant immune response are considered pathogenic mechanisms for CS. Certain environmental and occupational exposures may predispose to sarcoidosis, such as agricultural workers, firefighters, and those exposed to insecticides and microbial bioaerosols in mold. Sarcoidosis may also be more common following exposure to infectious microorganisms such as <italic toggle="yes">Chlamydophila pneumoniae</italic>,&#x000a0;<italic toggle="yes">Propionibacterium</italic>, and mycobacteria.<xref ref-type="bibr" rid="article-142599.r8">[8]</xref><xref ref-type="bibr" rid="article-142599.r9">[9]</xref>&#x000a0;One such study of 25 patients with sarcoidosis and 25 controls demonstrated mycobacteria in 60% of the sarcoid specimens but none of the controls.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref></p>
        <p>Cardiac sarcoidosis is also known to recur in the transplanted organs of patients with sarcoidosis who undergo a heart-lung transplant. Evidence exists of sarcoidosis in a nonsarcoid recipient of a heart transplant from a donor with sarcoidosis; this finding supports the hypothesis that the disease is secondary to an immunological or infectious process.<xref ref-type="bibr" rid="article-142599.r7">[7]</xref><xref ref-type="bibr" rid="article-142599.r10">[10]</xref></p>
      </sec>
      <sec id="article-142599.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of&#x000a0;CS in the United States and Europe is 10 to 40 persons per 100,000. The prevalence of CS is higher in Black patients (35.5 per 100,000) than in White patients (10.9 per 100,000).&#x000a0;The clinical diagnosis of&#x000a0;CS is made in only 5% of patients with sarcoidosis. However, autopsy studies reveal cardiac involvement in at least 25% of patients with&#x000a0;extracardiac sarcoidosis. Additionally, cardiac magnetic resonance imaging (CMR) and autopsy studies of patients with sarcoidosis have detected evidence of&#x000a0;CS in up to 26% of patients who remained asymptomatic.<xref ref-type="bibr" rid="article-142599.r11">[11]</xref>&#x000a0;</p>
        <p>In the United States, the mean age of diagnosis of CS is 53 years, with a slight preponderance in women (58%).<xref ref-type="bibr" rid="article-142599.r12">[12]</xref>&#x000a0;The incidence of sarcoidosis and its associated mortality rate is exceptionally high in Black women; a single study reported a prevalence of 2% in this patient population.<xref ref-type="bibr" rid="article-142599.r5">[5]</xref></p>
        <p>The clinical presentation of sarcoidosis seems to differ among ethnic groups. Lupus pernio is more common in Puerto Rican and Black patients, while erythema nodosum is more prevalent in patients of European descent.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref>&#x000a0;Although the rates of sarcoidosis are low in Japan, when sarcoidosis is present, CS is a common manifestation. Autopsy and imaging studies in Japan reveal a prevalence of CS approaching 50%.<xref ref-type="bibr" rid="article-142599.r13">[13]</xref>&#x000a0;Patients with sarcoidosis from Japan also have a higher incidence of cardiac death than similar patients from other countries.<xref ref-type="bibr" rid="article-142599.r13">[13]</xref></p>
      </sec>
      <sec id="article-142599.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The natural course of sarcoidosis and CS is unpredictable. Patients demonstrate variable inflammatory responses. Some patients respond with minimal local inflammation, while others respond with extensive inflammation and fibrosis.&#x000a0;Sarcoidosis is characterized by significant activation of macrophages and CD4+ T cells. This&#x000a0;activation increases the production of tumor necrosis factor-alpha (TNF-&#x003b1;), interferon-gamma (IFN-&#x003b3;), and the expression of the amyloid A protein.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref>&#x000a0;The signature lesions of&#x000a0;CS are noncaseating granulomas, particularly within the interventricular septum and inferior left ventricle. While granulomas can be found in epicardial, myocardial, and endocardial tissue, the subepicardium and myocardium are most commonly involved, while the endocardium is typically spared.<xref ref-type="bibr" rid="article-142599.r5">[5]</xref><xref ref-type="bibr" rid="article-142599.r14">[14]</xref>&#x000a0;</p>
        <p>Granulomatous involvement of the interventricular septum explains the propensity for conduction system abnormalities. These dysrhythmias include varying degrees of&#x000a0;AV block, bundle branch blocks, ventricular arrhythmias, and supraventricular arrhythmias, of which atrial fibrillation is most common. Sarcoid granulomas&#x000a0;may involve the left ventricle and cause dilated cardiomyopathy, mitral valve dysfunction, papillary muscle involvement, and left ventricular aneurysms.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref>&#x000a0;</p>
        <p>Most patients with CS have a&#x000a0;reduced ejection fraction, but clinical heart failure is uncommon. In patients with known CS, the 10-year incidence of clinically evident heart failure is 3%; this is twice&#x000a0;that of the general population.<xref ref-type="bibr" rid="article-142599.r5">[5]</xref> Right ventricular&#x000a0;dysfunction in patients with sarcoidosis is usually a consequence of pulmonary fibrosis, pulmonary hypertension, or left ventricular dysfunction causing right heart failure; granulomatous infiltration of the right ventricle does occur.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref><xref ref-type="bibr" rid="article-142599.r15">[15]</xref></p>
        <p>
<bold>Isolated Cardiac Sarcoidosis Versus Systemic Sarcoidosis With Cardiac Manifestations</bold>
</p>
        <p>There is evidence that isolated&#x000a0;CS, defined as cardiac involvement without systemic signs of sarcoidosis, may&#x000a0;confer a different clinical picture and prognosis than systemic sarcoidosis with cardiac involvement. Autopsy and imaging studies estimate that 25% of patients with evidence of CS have isolated CS. Many studies have shown that patients with isolated CS have worse prognoses than patients with systemic sarcoidosis and cardiac involvement. Patients with isolated CS typically present with worse left ventricular function and higher rates of ventricular arrhythmia. However, it is unclear whether these findings relate to the disease process or delayed diagnosis due to a lack of systemic manifestations.<xref ref-type="bibr" rid="article-142599.r1">[1]</xref></p>
      </sec>
      <sec id="article-142599.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The heart is the third-most common site of involvement in systemic sarcoidosis following the lungs and lymph nodes. The gross pathological examination of autopsy specimens of patients with CS&#x000a0;typically reveals patchy myocardial fibrosis inconsistent with a&#x000a0;specific coronary artery distribution.<xref ref-type="bibr" rid="article-142599.r14">[14]</xref>&#x000a0;Cardiac granulomas grossly appear as&#x000a0;tan, yellow, or brown nodular masses, measure a few millimeters in greatest diameter, and have well-defined margins. Pericardial and endocardial granulomas appear to be an extension of myocardial involvement.</p>
        <p>Noncaseating granulomas are the&#x000a0;characteristic&#x000a0;histopathological finding of endomyocardial CS. Sarcoid granulomas can be differentiated from other granulomas due to their compact appearance, epithelioid cell abundance, confluent fibrosis, and fatty infiltration.<xref ref-type="bibr" rid="article-142599.r16">[16]</xref><xref ref-type="bibr" rid="article-142599.r17">[17]</xref>&#x000a0;The granulomas comprise macrophages, epithelial cells, and T lymphocytes.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref>&#x000a0;Multinucleated giant cells cluster peripherally in a linear fashion and may have cytoplasmic inclusions such as&#x000a0;Schaumann or asteroid bodies.<xref ref-type="bibr" rid="article-142599.r17">[17]</xref></p>
      </sec>
      <sec id="article-142599.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>The most common presenting symptoms of&#x000a0;CS&#x000a0;include palpitations, presyncope, and syncope related to various arrhythmias, including AV blocks, atrial fibrillation, or other supraventricular and ventricular tachycardia.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref><xref ref-type="bibr" rid="article-142599.r18">[18]</xref><xref ref-type="bibr" rid="article-142599.r19">[19]</xref><xref ref-type="bibr" rid="article-142599.r2">[2]</xref>&#x000a0;Presyncope and syncope may be indicative of underlying life-threatening arrhythmias,&#x000a0;such as high-grade AV block or ventricular tachycardia, which can precipitate sudden cardiac death.<xref ref-type="bibr" rid="article-142599.r5">[5]</xref><xref ref-type="bibr" rid="article-142599.r20">[20]</xref>&#x000a0;One small study found AV block as the first manifestation of CS in more than 40% of patients; the second-most common presenting symptom in this study of patients with CS was ventricular tachycardia (28%).<xref ref-type="bibr" rid="article-142599.r21">[21]</xref>&#x000a0;Alternatively,&#x000a0;arrhythmias&#x000a0;can lead to more subtle, chronic symptoms of fatigue, exertional dyspnea, and chest discomfort.<xref ref-type="bibr" rid="article-142599.r22">[22]</xref>&#x000a0;The predominant symptomatology of patients with right ventricular dysfunction due to left ventricular dysfunction or pulmonary hypertension from pulmonary sarcoidosis may be dyspnea and lower extremity edema.</p>
        <p>Patients may present with heart failure symptoms such as exertional dyspnea, orthopnea, or paroxysmal nocturnal dyspnea due to dilated or restrictive cardiomyopathy. Patients can also present with respiratory symptoms due to concomitant pulmonary sarcoidosis. Sarcoidosis can also cause coronary vasculitis, and patients may present with symptoms of myocardial ischemia.&#x000a0;</p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>The physical examination of a patient may reveal tachycardia, bradycardia, an irregular pulse, pedal edema, or jugular venous distention. A loud second heart sound may indicate pulmonary hypertension.&#x000a0;A third or fourth heart sound can indicate left ventricular dysfunction.&#x000a0;Systolic or diastolic murmurs at the apex are common in mitral valve involvement.<xref ref-type="bibr" rid="article-142599.r23">[23]</xref></p>
        <p>Sarcoidosis usually involves multiple organ systems. Pulmonary symptoms are present in 90% of patients; cutaneous, ocular, and neurological manifestations are also common. Erythema nodosum, lupus pernio, uveitis, cranial nerve palsies, or seizures may be indicative of systemic sarcoidosis.<xref ref-type="bibr" rid="article-142599.r24">[24]</xref></p>
      </sec>
      <sec id="article-142599.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of&#x000a0;CS can be histological or clinical. A definite diagnosis of CS can be made with histological&#x000a0;evidence&#x000a0;of myocardial noncaseating granulomas in tissue obtained via endomyocardial biopsy in the absence of another identified noncaseating granulomatous disease.&#x000a0;However, endomyocardial biopsy has a 25% to 36% sensitivity for CS due to patchy involvement of the myocardium.&#x000a0;The diagnostic sensitivity of endomyocardial biopsy can be increased to approximately 50% using electrophysiologic mapping.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref></p>
        <p>
<bold>Electrocardiography</bold>
</p>
        <p>Electrocardiography (ECG) can identify rhythm abnormalities. However, when patients present with palpitations as the only symptoms, ambulatory rhythm monitoring&#x000a0;is superior at identifying transient AV blocks and ventricular tachycardia. The diagnostic yield can be low; less than 10% of patients with asymptomatic CS have an abnormal ECG.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref><xref ref-type="bibr" rid="article-142599.r25">[25]</xref></p>
        <p>
<bold>Echocardiography&#x000a0;</bold>
</p>
        <p>Echocardiography in patients with CS may reveal thinning of the basal septum, akinetic and dyskinetic regional wall motion abnormalities not in a coronary artery distribution, left ventricular systolic dysfunction, and left ventricular dilation with or without aneurysm.<xref ref-type="bibr" rid="article-142599.r26">[26]</xref>&#x000a0;However, echocardiography is an insensitive tool to detect the early stages of the disease, and patients with cardiac sarcoidosis can have a normal echocardiogram.&#x000a0;</p>
        <p>
<bold>Cardiac&#x000a0;Magnetic Resonance Imaging</bold>
</p>
        <p>Cardiac magnetic resonance imaging<bold>&#x000a0;</bold>(CMR)<bold>&#x000a0;</bold>provides valuable information about structural cardiac abnormalities. Wall thinning, aneurysms, and chamber dilation are commonly seen in patients with CS.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref>&#x000a0;Barring contraindications, gadolinium administration is recommended. Late gadolinium enhancement is a critical diagnostic tool in patients with CS that usually indicates myocardial fibrosis but can also indicate edema. Enhancement is primarily seen in the midseptum and left ventricular subepicardium and myocardium, but not the endocardium. Late gadolinium enhancement is an especially poor prognostic indicator.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref>&#x000a0;The sensitivity of CMR for detecting CS is 75% to 100%, and the specificity is 76% to 100%.<xref ref-type="bibr" rid="article-142599.r27">[27]</xref></p>
        <p>
<bold>Fluorodeoxyglucose F 18 Positron Emission Tomography</bold>
</p>
        <p>Fluorodeoxyglucose F 18 positron emission tomography<bold>&#x000a0;</bold>(FDG-PET)<bold>&#x000a0;</bold>is a functional study employing labeled FDG as a surrogate for glucose. Inflammatory cells have a very high metabolic rate; a positive&#x000a0;FDG-PET correlates with inflammation. However, myocardial glucose uptake must be suppressed to highlight the inflammatory cells.<xref ref-type="bibr" rid="article-142599.r28">[28]</xref>&#x000a0;Suppression is achieved by fasting before the test, consuming a low-carbohydrate and high-fat diet the day before the fast, avoiding exercise during the fast, an altered insulin regimen for people with diabetes the day before the test, and avoiding peritoneal dialysis the day before the test.<xref ref-type="bibr" rid="article-142599.r29">[29]</xref>&#x000a0;</p>
        <p>FDG-PET is staged with cardiac and whole-body imaging&#x000a0;and may identify high-yield biopsy sites with active inflammation. FDG uptake in CS can be focal, diffuse, or patchy, and with or without perfusion abnormalities, depending on whether there is inflammation or scar formation. FDG&#x000a0;uptake can be decreased in coronary artery disease or ischemia. The sensitivity of FDG-PET is estimated at 89% and specificity at 78%.<xref ref-type="bibr" rid="article-142599.r28">[28]</xref>&#x000a0;</p>
        <p>FDG-PET and CMR are often used in combination to&#x000a0;add valuable information about active inflammation, extracardiac involvement, and cardiac structural details.<xref ref-type="bibr" rid="article-142599.r30">[30]</xref>&#x000a0;These tests can be used individually or together to assess the effectiveness of therapeutic interventions.</p>
        <p>
<bold>Endomyocardial Biopsy</bold>
</p>
        <p>Biopsy showing noncaseating granulomas is the only definitive way to diagnose CS, but the diagnostic yield is low at 25% to 36% due to the patchy and focal nature of the disease. In patients with extracardiac manifestations of sarcoidosis, an&#x000a0;extracardiac biopsy site is preferred due to a higher diagnostic yield and lower rate of complications. If an endomyocardial biopsy is required, FDG-PET or CMR may identify a suitable biopsy site; patients undergoing an electrophysiologic study should be mapped to increase the diagnostic yield of an endomyocardial biopsy. In cases of isolated CS or when an extracardiac biopsy site is nondiagnostic, endomyocardial biopsy may be&#x000a0;required to confirm a diagnosis of CS.<xref ref-type="bibr" rid="article-142599.r2">[2]</xref></p>
      </sec>
      <sec id="article-142599.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of&#x000a0;CS aims to slow disease progression, reduce the risk of sudden cardiac death, treat heart failure, and manage arrhythmias.&#x000a0;</p>
        <p>
<bold>Immunosuppressive Therapy</bold>
</p>
        <p>Immunosuppressive therapy is recommended for patients with CS with evidence of cardiac involvement, such as heart block, ventricular arrhythmias, or heart failure, and evidence of active inflammation on histological examination or FDG-PET. The initial therapeutic intervention for CS is immunosuppression with corticosteroids to reduce inflammation and fibrosis; randomized control trials investigating the efficacy of corticosteroids have not been performed.<xref ref-type="bibr" rid="article-142599.r25">[25]</xref>&#x000a0;Corticosteroids have been reported to reduce the burden of ventricular tachycardia, reverse AV block, and improve LVEF.<xref ref-type="bibr" rid="article-142599.r31">[31]</xref>&#x000a0;The goal of corticosteroid immunosuppression is early initiation of therapy before the&#x000a0;LVEF decreases and to reduce corticosteroid exposure.&#x000a0;</p>
        <p>A Finnish study of 110 patients, 93% of whom received immunosuppressive therapy, revealed that cardiac transplant-free survival at 1, 5, and 10 years was 97%, 90%, and 83%, respectively.<xref ref-type="bibr" rid="article-142599.r32">[32]</xref>&#x000a0;FDG-PET is employed to assess the response to immunosuppression 3 months after initiating therapy. If FDG-PET performed after 3 months of treatment reveals reduced uptake, the corticosteroids may be tapered to complete a 12-month course of therapy. The Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial (CHASM CS-RCT) is currently being conducted to compare methotrexate with standard- and low-dose prednisone for the initial treatment of CS.</p>
        <p>Corticosteroid-sparing&#x000a0;agents&#x000a0;are regularly used in conjunction with corticosteroids to minimize steroid exposure. While no consensus guidelines exist, many clinicians use methotrexate or mycophenolate mofetil with steroids or in patients who appear to be steroid-resistant. Other therapeutic agents used include azathioprine, cyclophosphamide, and leflunomide.<xref ref-type="bibr" rid="article-142599.r5">[5]</xref>&#x000a0;Immunologic therapies such as infliximab, adalimumab, and rituximab are considered third- or fourth-line agents in treating CS because of potential complications.&#x000a0;</p>
        <p>
<bold>Managing Dysrhythmias in Cardiac Sarcoidosis</bold>
</p>
        <p>When managing conduction abnormalities in patients with CS, it is recommended to follow the 2012 ACCF/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Pacemaker implantation may be helpful in patients with CS and a reversible conduction block. An implantable cardioverter-defibrillator (ICD) may be an option for those requiring permanent pacing. The guidelines suggest immunosuppression can be useful in patients with CS and Mobitz type II or third-degree AV block.<xref ref-type="bibr" rid="article-142599.r33">[33]</xref></p>
        <p>Anticoagulation is recommended for patients with CS and atrial fibrillation, as guided by the CHA<sub>2</sub>DS<sub>2</sub>-VASc score. A therapeutic electrophysiology study may be performed in patients with CS and atrial arrhythmias, except for atrial fibrillation. Class I antiarrhythmic medications carry a class III indication in patients with CS and arrhythmias.<xref ref-type="bibr" rid="article-142599.r33">[33]</xref></p>
        <p>The consensus&#x000a0;guidelines suggest that an FDG-PET is useful for identifying&#x000a0;inflamed myocardium in patients with CS. Furthermore, immunosuppressive therapy can be useful in CS patients with unustained ventricular ectopy or sustained ventricular arrhythmias. Antiarrhythmic medications and catheter ablation are recommended for&#x000a0;ventricular tachycardia&#x000a0;unresponsive to immunosuppression. The initial therapeutic strategy for patients with CS and ventricular tachycardia is corticosteroids and amiodarone; catheter ablation is reserved for patients refractory to medical therapy.<xref ref-type="bibr" rid="article-142599.r33">[33]</xref>&#x000a0;</p>
        <p>An ICD is recommended for patients with CS&#x000a0;and a spontaneous sustained ventricular arrhythmia that includes prior cardiac arrest or those with LVEF less than 35% despite medical therapy and immunosuppression. ICD therapy is useful in patients with CS with a pacer indication, unexplained syncope or presyncope of likely arrhythmic etiology, or inducible sustained ventricular arrhythmia. ICD therapy may be considered in patients with LVEF of 36% to 49% and RV ejection fraction less than 40% on optimal medical therapy and immunosuppression. ICD therapy is not recommended in patients with incessant ventricular arrhythmias or New York Heart Association class IV heart failure. Additionally, ICD therapy is not indicated in patients with no history of arrhythmia or syncope, no pacing indication, normal LV/RV function, absent late gadolinium enhancement during CMR,&#x000a0;or a negative electrophysiologic study.<xref ref-type="bibr" rid="article-142599.r33">[33]</xref></p>
      </sec>
      <sec id="article-142599.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Cardiac sarcoidosis is a challenging diagnosis. Myocarditis&#x000a0;can be especially difficult to distinguish from cardiac sarcoidosis due to similar clinical presentations, including ventricular arrhythmias, heart failure, late gadolinium enhancement on CMR, and abnormal uptake on FDG-PET.&#x000a0;Viral myocarditis may or may not be preceded by a viral prodrome, and giant cell myocarditis usually has a more fulminant course.<xref ref-type="bibr" rid="article-142599.r34">[34]</xref>&#x000a0;An endomyocardial biopsy may be needed to distinguish these from sarcoidosis.</p>
        <p>Cardiomyopathies, particularly arrhythmogenic right ventricular cardiomyopathy&#x000a0;(ARVC), is another condition that can present with findings very similar to CS.<xref ref-type="bibr" rid="article-142599.r35">[35]</xref>&#x000a0;Ventricular arrhythmias are common in both conditions; AV block and heart failure symptoms are more common in CS.<xref ref-type="bibr" rid="article-142599.r35">[35]</xref><xref ref-type="bibr" rid="article-142599.r36">[36]</xref>&#x000a0;Ventricular septal late gadolinium enhancement is usually absent in patients with ARVC, while intramyocardial fat infiltration is more likely.<xref ref-type="bibr" rid="article-142599.r37">[37]</xref>&#x000a0;Extracardiac manifestations consistent with sarcoidosis are also more likely to favor CS.</p>
        <p>Late gadolinium enhancement on CMR is observed in many pathologic conditions, including myocardial infarction, cardiac amyloidosis, hypertrophic cardiomyopathy, Fabry disease, and hereditary hemochromatosis.&#x000a0;An enhancement pattern within the distribution of coronary artery supply can help distinguish CS from scarring secondary to prior myocardial infarction and CS. Hereditary hemochromatosis can present with arrhythmias and heart failure but is associated with skin hyperpigmentation, diabetes, and evidence of reduced T2-weighted times on CMR.<xref ref-type="bibr" rid="article-142599.r38">[38]</xref></p>
        <p>The myocardial granulomas characteristic of CS can also be seen in tuberculosis, fungal infections, systemic vasculitis, and immunodeficiencies.<xref ref-type="bibr" rid="article-142599.r39">[39]</xref>&#x000a0;However, these conditions have significantly different clinical presentations, which can be differentiated&#x000a0;by historical and physical examination findings in addition to diagnostic testing.</p>
      </sec>
      <sec id="article-142599.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with systemic sarcoidosis and CS have a worse prognosis than patients with extrapulmonary sarcoidosis without cardiac involvement. A history of sustained ventricular tachycardia, an increased left ventricular end-diastolic diameter, and an increased NYHA class are independent predictors of mortality in patients with CS.<xref ref-type="bibr" rid="article-142599.r32">[32]</xref>&#x000a0;Heart failure as a clinical manifestation and reduced&#x000a0;LVEF&#x000a0;carry an especially poor prognosis with a reported 10-year survival of 19 % to 53% in the absence of cardiac transplant.<xref ref-type="bibr" rid="article-142599.r40">[40]</xref></p>
        <p>Cardiac sarcoidosis carries a poor prognosis compared to other forms of sarcoidosis.<xref ref-type="bibr" rid="article-142599.r18">[18]</xref>&#x000a0;It is unclear whether silent CS has a better prognosis than CS with clinical manifestations. However, patients with asymptomatic&#x000a0;CS and a benign course might initially present with sudden cardiac arrest. Patients with CS and evidence of&#x000a0;late gadolinium enhancement&#x000a0;on CMR or abnormal uptake and perfusion defects on FDG-PET have an increased risk of VT and cardiovascular death.<xref ref-type="bibr" rid="article-142599.r41">[41]</xref>&#x000a0;</p>
        <p>Right ventricular dysfunction and RV&#x000a0;late gadolinium enhancement may also have prognostic implications. Among 260 biopsy-proven patients with CS, RV systolic function was independently associated with all-cause mortality. In contrast, right ventricular late gadolinium enhancement was associated with sudden cardiac death and ventricular arrhythmia.<xref ref-type="bibr" rid="article-142599.r42">[42]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-142599.s12" sec-type="Complications">
        <title>Complications</title>
        <p>If untreated,&#x000a0;CS usually leads to dilated cardiomyopathy and an increased risk of ventricular arrhythmias. Untreated or refractory pulmonary sarcoidosis that progresses to pulmonary fibrosis can lead to right heart failure.<xref ref-type="bibr" rid="article-142599.r15">[15]</xref><xref ref-type="bibr" rid="article-142599.r2">[2]</xref>&#x000a0;Sudden cardiac death is the most feared complication of CS, warranting risk stratification and evaluation for an ICD.<xref ref-type="bibr" rid="article-142599.r20">[20]</xref></p>
        <p>The following complications are also commonly encountered in patients with CS:</p>
        <list list-type="bullet">
          <list-item>
            <p>Left and right heart failure</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy with or without heart failure</p>
          </list-item>
          <list-item>
            <p>Ventricular arrhythmia</p>
          </list-item>
          <list-item>
            <p>Bradyarrhythmias, such as variable degrees of atrioventricular block, including third-degree heart block</p>
          </list-item>
          <list-item>
            <p>Sudden cardiac death</p>
          </list-item>
          <list-item>
            <p>Atrial tachycardia, including atrial fibrillation</p>
          </list-item>
          <list-item>
            <p>Pulmonary hypertension with subsequent right heart failure</p>
          </list-item>
          <list-item>
            <p>Coronary vasculitis and myocardial ischemia.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-142599.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Cardiac sarcoidosis is a determinant of prognosis in patients with systemic sarcoidosis. CS portends an increased risk of ventricular arrhythmias and sudden cardiac death. Patients with cardiac sarcoidosis should be aware of the progressive nature of the disease and the need for repeat evaluation and imaging to guide timely therapy. Patients can have symptoms of multisystem involvement and might need to see an organ-specific specialist for appropriate management.&#x000a0;Patients with this condition need to initiate immunosuppression promptly to decrease the progression of the disease process in the heart.</p>
      </sec>
      <sec id="article-142599.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cardiac sarcoidosis is best managed by an interprofessional approach to enhance the chances of diagnosing CS and recognizing coexisting extracardiac manifestations of sarcoidosis.&#x000a0;CS&#x000a0;is a frequently missed diagnosis, given its rarity and the high index of suspicion needed to make the diagnosis. The combined effort of advanced imaging specialists, electrophysiologists, and interventional cardiologists is often required to diagnose CS.&#x000a0;Early diagnosis and immunosuppression initiation are clearly beneficial in reducing disease progression.<xref ref-type="bibr" rid="article-142599.r31">[31]</xref>&#x000a0;A holistic approach to management is recommended, with care coordination between primary care clinicians, cardiologists, pulmonologists, and immunologists. Electrophysiology support can help risk-stratify patients who need device implantation to prevent sudden cardiac death. Patient care is enhanced by involving advanced heart failure specialists to identify those who may benefit from referral for advanced heart failure therapies.<xref ref-type="bibr" rid="article-142599.r32">[32]</xref></p>
      </sec>
      <sec id="article-142599.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=142599&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=142599">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/cardiac-sarcoidosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=142599">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/142599/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=142599">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-142599.s16">
        <title>References</title>
        <ref id="article-142599.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okada</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Bravo</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Vita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Osborne</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Taqueti</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Skali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chareonthaitawee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dorbala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Carli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blankstein</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Isolated cardiac sarcoidosis: A focused review of an under-recognized entity.</article-title>
            <source>J Nucl Cardiol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>1136</fpage>
            <page-range>1136-1146</page-range>
            <pub-id pub-id-type="pmid">27613395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trivieri</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Spagnolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Birnie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kovacic</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Baughman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fayad</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Challenges in Cardiac and Pulmonary&#x000a0;Sarcoidosis: JACC State-of-the-Art Review.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2020</year>
            <month>Oct</month>
            <day>20</day>
            <volume>76</volume>
            <issue>16</issue>
            <fpage>1878</fpage>
            <page-range>1878-1901</page-range>
            <pub-id pub-id-type="pmid">33059834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birnie</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Nery</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Beanlands</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Cardiac Sarcoidosis.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>26</day>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>411</fpage>
            <page-range>411-21</page-range>
            <pub-id pub-id-type="pmid">27443438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schupp</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Freitag-Wolf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bargagli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mihailovi&#x00107;-Vu&#x0010d;ini&#x00107;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rottoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grubanovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jochens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tittmann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schnerch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jovanovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Filipovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Videnovic-Ivanovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bresser</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jonkers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Reilly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Gaede</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Zabel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dubaniewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kieszko</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Milanowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nther</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weihrich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petrek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kolek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>O'Beirne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haraldsdottir</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Jorundsdottir</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Costabel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bonella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wallaert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pero&#x00161;-Golubi&#x0010d;i&#x00107;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Luisetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kadija</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Pabst</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Groh&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Strausz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Va&#x00161;&#x000e1;kov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sterclova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Millar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Homolka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Slov&#x000e1;kov&#x000e1;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kendrick</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Crawshaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wuyts</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pfeifer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valeyre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Poletti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Prasse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krawczak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Quernheim</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Phenotypes of organ involvement in sarcoidosis.</article-title>
            <source>Eur Respir J</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>51</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29371378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilotra</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pavlovic</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Houston</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Chasler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chrispin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sharp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Blankstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.</article-title>
            <source>J Card Fail</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-132</page-range>
            <pub-id pub-id-type="pmid">34260889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Moller</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Etiologies of Sarcoidosis.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-18</page-range>
            <pub-id pub-id-type="pmid">25771769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosoda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sasagawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of sarcoidosis: new frontiers to explore.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>424</fpage>
            <page-range>424-8</page-range>
            <pub-id pub-id-type="pmid">12172447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Bresnitz</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Rossman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Barnard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frederick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terrin</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Weinberger</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Moller</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>McLennan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hunninghake</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>DePalo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baughman</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Iannuzzi</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Knatterud</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Teirstein</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Yeager</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Johns</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Rabin</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Rybicki</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Cherniack</surname>
                <given-names>R</given-names>
              </name>
              <collab>ACCESS Research Group</collab>
            </person-group>
            <article-title>A case control etiologic study of sarcoidosis: environmental and occupational risk factors.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2004</year>
            <month>Dec</month>
            <day>15</day>
            <volume>170</volume>
            <issue>12</issue>
            <fpage>1324</fpage>
            <page-range>1324-30</page-range>
            <pub-id pub-id-type="pmid">15347561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kern</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Neill</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wrenn</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Varone</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Investigation of a unique time-space cluster of sarcoidosis in firefighters.</article-title>
            <source>Am Rev Respir Dis</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>4 Pt 1</issue>
            <fpage>974</fpage>
            <page-range>974-80</page-range>
            <pub-id pub-id-type="pmid">8214953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burke</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Delprado</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Spratt</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Transmission of sarcoidosis via cardiac transplantation.</article-title>
            <source>Lancet</source>
            <year>1990</year>
            <month>Dec</month>
            <day>22-29</day>
            <volume>336</volume>
            <issue>8730</issue>
            <fpage>1579</fpage>
            <pub-id pub-id-type="pmid">1979389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Cawley</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Heitner</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Klem</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jaroudi</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Meine</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Judd</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Detection of myocardial damage in patients with sarcoidosis.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>Nov</month>
            <day>17</day>
            <volume>120</volume>
            <issue>20</issue>
            <fpage>1969</fpage>
            <page-range>1969-77</page-range>
            <pub-id pub-id-type="pmid">19884472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parrish</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Sicignano</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis in the United States Military Health System.</article-title>
            <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
            <year>2018</year>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>261</fpage>
            <page-range>261-267</page-range>
            <pub-id pub-id-type="pmid">32476911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>OP</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis around the world.</article-title>
            <source>Clin Chest Med</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>357</fpage>
            <page-range>357-63, vii</page-range>
            <pub-id pub-id-type="pmid">18539231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynch</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bradfield</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fishbein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shivkumar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>372</fpage>
            <page-range>372-90</page-range>
            <pub-id pub-id-type="pmid">25007089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubrey</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Sarcoid heart disease.</article-title>
            <source>Postgrad Med J</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>83</volume>
            <issue>984</issue>
            <fpage>618</fpage>
            <page-range>618-23</page-range>
            <pub-id pub-id-type="pmid">17916869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cha</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Indirect pathological indicators for cardiac sarcoidosis on endomyocardial biopsy.</article-title>
            <source>J Pathol Transl Med</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>396</fpage>
            <page-range>396-410</page-range>
            <pub-id pub-id-type="pmid">32717775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lagana</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Parwani</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Cardiac sarcoidosis: a pathology-focused review.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>134</volume>
            <issue>7</issue>
            <fpage>1039</fpage>
            <page-range>1039-46</page-range>
            <pub-id pub-id-type="pmid">20586635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Donnino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Prystowsky</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Prystowsky</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cardiac sarcoidosis.</article-title>
            <source>Am Heart J</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-21</page-range>
            <pub-id pub-id-type="pmid">19081391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rybicki</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Major</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Popovich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maliarik</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Iannuzzi</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.</article-title>
            <source>Am J Epidemiol</source>
            <year>1997</year>
            <month>Feb</month>
            <day>01</day>
            <volume>145</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-41</page-range>
            <pub-id pub-id-type="pmid">9012596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Houston</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cardiac sarcoidosis: clinical manifestations, imaging characteristics, and therapeutic approach.</article-title>
            <source>Clin Med Insights Cardiol</source>
            <year>2014</year>
            <volume>8</volume>
            <issue>Suppl 1</issue>
            <fpage>31</fpage>
            <page-range>31-7</page-range>
            <pub-id pub-id-type="pmid">25452702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ekstr&#x000f6;m</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lehtonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nordenswan</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>M&#x000e4;yr&#x000e4;np&#x000e4;&#x000e4;</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>R&#x000e4;is&#x000e4;nen-Sokolowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kandolin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simonen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pietil&#x000e4;-Effati</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alatalo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Utriainen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rissanen</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Haataja</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kokkonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vihinen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miettinen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaikkonen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kerola</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kupari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries.</article-title>
            <source>Eur Heart J</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>40</volume>
            <issue>37</issue>
            <fpage>3121</fpage>
            <page-range>3121-3128</page-range>
            <pub-id pub-id-type="pmid">31230070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wung</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Bradyarrhythmias: Clinical Presentation, Diagnosis, and Management.</article-title>
            <source>Crit Care Nurs Clin North Am</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-308</page-range>
            <pub-id pub-id-type="pmid">27484658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>HD</given-names>
              </name>
            </person-group>
            <article-title>Cardiac Examination and Evaluation of Murmurs.</article-title>
            <source>Pediatr Rev</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>7</issue>
            <fpage>375</fpage>
            <page-range>375-382</page-range>
            <pub-id pub-id-type="pmid">34210756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llanos</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hamzeh</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis.</article-title>
            <source>Med Clin North Am</source>
            <year>2019</year>
            <month>May</month>
            <volume>103</volume>
            <issue>3</issue>
            <fpage>527</fpage>
            <page-range>527-534</page-range>
            <pub-id pub-id-type="pmid">30955519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kusano</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Satomi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of cardiac sarcoidosis.</article-title>
            <source>Heart</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>102</volume>
            <issue>3</issue>
            <fpage>184</fpage>
            <page-range>184-90</page-range>
            <pub-id pub-id-type="pmid">26643814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burstow</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Tajik</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>DeRemee</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Taliercio</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Two-dimensional echocardiographic findings in systemic sarcoidosis.</article-title>
            <source>Am J Cardiol</source>
            <year>1989</year>
            <month>Feb</month>
            <day>15</day>
            <volume>63</volume>
            <issue>7</issue>
            <fpage>478</fpage>
            <page-range>478-82</page-range>
            <pub-id pub-id-type="pmid">2916434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blankstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chandrashekhar</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The Challenges of Diagnosing Cardiac Sarcoidosis.</article-title>
            <source>JACC Cardiovasc Imaging</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>1534</fpage>
            <page-range>1534-1536</page-range>
            <pub-id pub-id-type="pmid">29216980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bois</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Muser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chareonthaitawee</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>PET/CT Evaluation of Cardiac Sarcoidosis.</article-title>
            <source>PET Clin</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>223</fpage>
            <page-range>223-232</page-range>
            <pub-id pub-id-type="pmid">30826020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Optimizing cardiac sarcoid imaging with FDG PET: Lessons from studies of physiologic regulation of myocardial fuel substrate utilization.</article-title>
            <source>J Nucl Cardiol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>490</fpage>
            <page-range>490-493</page-range>
            <pub-id pub-id-type="pmid">30225815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blankstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Osborne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Kazemian</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Tokuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Padera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hainer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Dorbala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Carli</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Feb</month>
            <day>04</day>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>329</fpage>
            <page-range>329-36</page-range>
            <pub-id pub-id-type="pmid">24140661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kusano</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Effect of corticosteroid on arrhythmic events in patients with cardiac sarcoidosis.</article-title>
            <source>J Cardiol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>5</issue>
            <fpage>326</fpage>
            <page-range>326-7</page-range>
            <pub-id pub-id-type="pmid">24169440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kandolin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lehtonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Airaksinen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vihinen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miettinen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ylitalo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaikkonen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tuohinen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haataja</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kerola</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kokkonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pelkonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pietil&#x000e4;-Effati</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Utrianen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kupari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Feb</month>
            <day>17</day>
            <volume>131</volume>
            <issue>7</issue>
            <fpage>624</fpage>
            <page-range>624-32</page-range>
            <pub-id pub-id-type="pmid">25527698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birnie</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Sauer</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Bogun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Culver</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Duvernoy</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cosedis Nielsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Ohe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Raatikainen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soejima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.</article-title>
            <source>Heart Rhythm</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>1305</fpage>
            <page-range>1305-23</page-range>
            <pub-id pub-id-type="pmid">24819193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doltra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amundsen</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Gebker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fleck</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kelle</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Emerging concepts for myocardial late gadolinium enhancement MRI.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>185</fpage>
            <page-range>185-90</page-range>
            <pub-id pub-id-type="pmid">23909638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philips</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Madhavan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>te Riele</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tichnell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bhonsale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nazarian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tandri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear.</article-title>
            <source>Circ Arrhythm Electrophysiol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-6</page-range>
            <pub-id pub-id-type="pmid">24585727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasaiwala</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delpriore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leya</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gagermeier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Akar</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Santucci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dajani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Picken</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Basso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wilber</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia.</article-title>
            <source>J Cardiovasc Electrophysiol</source>
            <year>2009</year>
            <month>May</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>473</fpage>
            <page-range>473-6</page-range>
            <pub-id pub-id-type="pmid">19017339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tandri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Nasir</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dalal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bomma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bluemke</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Magnetic resonance imaging of arrhythmogenic right ventricular dysplasia: sensitivity, specificity, and observer variability of fat detection versus functional analysis of the right ventricle.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2006</year>
            <month>Dec</month>
            <day>05</day>
            <volume>48</volume>
            <issue>11</issue>
            <fpage>2277</fpage>
            <page-range>2277-84</page-range>
            <pub-id pub-id-type="pmid">17161260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Holden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prescott</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Charrier</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Bunce</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Firmin</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Wonke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pennell</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.</article-title>
            <source>Eur Heart J</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>23</issue>
            <fpage>2171</fpage>
            <page-range>2171-9</page-range>
            <pub-id pub-id-type="pmid">11913479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasse</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Diagnosis, Differential Diagnosis, and Treatment of Sarcoidosis.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2016</year>
            <month>Aug</month>
            <day>22</day>
            <volume>113</volume>
            <issue>33-34</issue>
            <fpage>565</fpage>
            <page-range>565-74</page-range>
            <pub-id pub-id-type="pmid">27598883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiu</surname>
                <given-names>CZ</given-names>
              </name>
              <name>
                <surname>Nakatani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tachibana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohmori</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yamagishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kitakaze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomoike</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miyatake</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis.</article-title>
            <source>Am J Cardiol</source>
            <year>2005</year>
            <month>Jan</month>
            <day>01</day>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-6</page-range>
            <pub-id pub-id-type="pmid">15619415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hulten</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parrish</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bittencourt</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Di Carli</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Blankstein</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Presence of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Among Patients With Suspected Cardiac Sarcoidosis Is Associated With Adverse Cardiovascular Prognosis: A Systematic Review and Meta-Analysis.</article-title>
            <source>Circ Cardiovasc Imaging</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>e005001</fpage>
            <pub-id pub-id-type="pmid">27621357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142599.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velangi</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kazmirczak</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Okasha</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>von Wald</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roukoz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Farzaneh-Far</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nijjar</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Bhargava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perlman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ak&#x000e7;akaya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shenoy</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis.</article-title>
            <source>JACC Cardiovasc Imaging</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>1395</fpage>
            <page-range>1395-1405</page-range>
            <pub-id pub-id-type="pmid">31954639</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
